Modern antiretroviral regimens

Modern antiretroviral regimens

The article presents the results of major international studies (STARTMRK, ACTG A5257, SPRING 2, the SINGLE and FLAMINGO), which convincingly demonstrated the effectiveness and safety of drugs from the group of integrase inhibitors (raltegravir and dolutegravir) as part of ART regimens in HIV-infect...

Full description

Bibliographic Details
Main Author:	A. V. Kravchenko
Format:	Article
Language:	Russian
Published:	Remedium Group LLC 2016-12-01
Series:	Медицинский совет
Subjects:	hiv infection art integrase inhibitors raltegravir dolutegravir
Online Access:	https://www.med-sovet.pro/jour/article/view/1588

Similar Items

Raltegravir is the first HIV integrase inhibitor as part of antiretroviral treatment regimens
by: Aleksey Viktorovich Kravchenko, et al.
Published: (2010-11-01)

Integrase inhibitors versus efavirenz combination antiretroviral therapies for TB/HIV coinfection: a meta-analysis of randomized controlled trials
by: Yuanlu Shu, et al.
Published: (2021-05-01)

Are new antiretroviral treatments increasing the risks of clinical obesity?
by: Andrew Hill, et al.
Published: (2019-01-01)

HIV INTEGRASE INHIBITORS: THE BASIS OF EFFECTIVE AND SAFE ANTIRETROVIRAL THERAPY
by: V. I. SHAKHGILDYAN
Published: (2017-05-01)

Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients
by: Nicola Gianotti, et al.
Published: (2017-11-01)

Novel therapeutic strategies targeting HIV integrase
by: Quashie Peter K, et al.
Published: (2012-04-01)

Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study
by: José Ramón Santos, et al.
Published: (2023-06-01)

Cerebral function parameters in people with HIV switching integrase inhibitors: a randomized controlled trial
by: Borja Mora-Peris, et al.
Published: (2021-12-01)

HIV/HCV-coinfection: which role can new antiretrovirals such as integrase inhibitors play?
by: Vogel Martin, et al.
Published: (2009-11-01)

Temporary increase in circulating replication-competent latent HIV-infected resting CD4+ T cells after switch to an integrase inhibitor based antiretroviral regimenResearch in context
by: Roux-Cil Ferreira, et al.
Published: (2024-04-01)

Resistance to inhibitors of the human immunodeficiency virus type 1 integration
by: Daria J Hazuda

Evaluation of Circulating and Archived HIV-1 Integrase Drug-Resistance Variants among Patients on Third-Line ART in Cameroon: Implications for Dolutegravir-Containing Regimens in Resource-Limited Settings
by: Joseph Fokam, et al.
Published: (2022-12-01)

G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to Raltegravir whereas Y143C does not
by: Damond Florence, et al.
Published: (2011-08-01)

HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland
by: Parczewski Miłosz, et al.
Published: (2012-12-01)

Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence
by: Thibault Mesplède, et al.
Published: (2015-07-01)

Will Drug Resistance against Dolutegravir in Initial Therapy Ever Occur?
by: Mark eWainberg, et al.
Published: (2015-04-01)

HIV-1 Subtype C Drug Resistance Mutations in Heavily Treated Patients Failing Integrase Strand Transfer Inhibitor-Based Regimens in Botswana
by: Kaelo K. Seatla, et al.
Published: (2021-03-01)

Efficacy, safety, and tolerability of dolutegravir-based ART regimen in Durban, South Africa: a cohort study
by: Nivriti Hurbans, et al.
Published: (2024-03-01)

Raltegravir-Induced Adaptations of the HIV-1 Integrase: Analysis of Structure, Variability, and Mutation Co-occurrence
by: Lucas de Almeida Machado, et al.
Published: (2019-09-01)

HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study
by: Aurelio Orta-Resendiz, et al.
Published: (2020-02-01)

Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance
by: Eva Wolf, et al.
Published: (2021-09-01)

A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal function in HIV-1 antiretroviral naïve patients
by: Margherita Bracchi, et al.
Published: (2021-11-01)

A Comprehensive Literature Review of Treatment-Emergent Integrase Resistance with Dolutegravir-Based Regimens in Real-World Settings
by: Cassidy Henegar, et al.
Published: (2023-12-01)

Emergent dolutegravir resistance in integrase-naïve, treatment experienced patients from Zimbabwe
by: Linda A. Mandikiyana Chirimuta, et al.
Published: (2022-10-01)

Blood glucose trajectories and incidence of diabetes mellitus in Ugandan people living with HIV initiated on dolutegravir
by: Frank Mulindwa, et al.
Published: (2023-03-01)

EXPERIENCE WITH DOLUTEGRAVIR IN HIV PATIENTS AT A PUBLIC SECTOR HOSPITAL IN KARACHI, PAKISTAN
by: Farzana Batool, et al.
Published: (2021-10-01)

Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review
by: Kaiming Tao, et al.
Published: (2023-09-01)

New onset type 2 diabetes mellitus risks with integrase strand transfer inhibitors-based regimens: A systematic review and meta-analysis
by: Violet Dismas Kajogoo, et al.
Published: (2023-03-01)

Inhibition of HTLV-1 Infection by HIV-1 First- and Second-Generation Integrase Strand Transfer Inhibitors
by: Michał S. Barski, et al.
Published: (2019-08-01)

Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? a case report
by: Frank Mulindwa, et al.
Published: (2023-10-01)

A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection
by: Alexa Vyain Zhao, et al.
Published: (2022-10-01)

Resistance to Integrase Inhibitors
by: Mathieu Métifiot, et al.
Published: (2010-06-01)

R263K Mutation Leading to Failure of Dolutegravir-Based Treatment in a HIV Patient also Receiving Rifampicin: A Case Report
by: Jin Li, et al.
Published: (2023-05-01)

Virological and Immunological Outcomes of an Intensified Four-Drug versus a Standard Three-Drug Antiretroviral Regimen, Both Integrase Strand Transfer Inhibitor-Based, in Primary HIV Infection
by: Annalisa Mondi, et al.
Published: (2022-03-01)

Comparing Real-World Healthcare Costs Associated with Single-Tablet Regimens for HIV-1: The 2-Drug Regimen Dolutegravir/Lamivudine vs. Standard 3- or 4-Drug Regimens
by: Julie Priest, et al.
Published: (2023-08-01)

Cabotegravir Exposure of Zebrafish (<i>Danio rerio</i>) Embryos Impacts on Neurodevelopment and Behavior
by: Daniela Zizioli, et al.
Published: (2023-01-01)

Paediatric antiretroviral update
by: Gillian Sorour, et al.
Published: (2023-07-01)

The efficacy and safety of a therapy regimen including raltegravir and a fixed dose combination of lamivudine and abacavir in previously rifabutin-treated patients with tuberculosis and HIV infection
by: A V Kravchenko, et al.
Published: (2014-11-01)

Antiretroviral therapy containing raltegravir to prevent mother-to-child transmission of HIV in infected pregnant women
by: Diego M. Cecchini, et al.
Published: (2017-06-01)

HIV-1 resistance patterns to integrase inhibitors in Chilean patients with virological failure on raltegravir-containing regimens
by: Pablo Ferrer, et al.
Published: (2020-09-01)